Brief: Zelluna Submits Clinical Trial Application In The UK For First-In-Human Study Of Zi-Ma4-1
17/12/2025 16:29
Dec 17 (Reuters) - Zelluna ASA ZLNA.OL: REG-ZELLUNA REACHES MAJOR MILESTONE AND SUBMITS CLINICAL TRIAL APPLICATION IN THE UK FOR FIRST-IN-HUMAN STUDY OF ZI-MA4-1 (ZIMA-101), THE WORLD’S FIRST MAGE-A4-TARGETING TCR-NK CELL THERAPY FOR SOLID TUMOURS ON TRACK FOR INITIAL CLINICAL DATA IN MID-2026 Source text: ID:nGNEWrjkF Further company coverage: ZLNA.OL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant